Thymosin Beta-4

What it is

Thymosin Beta-4 is one of the more abundant regulatory proteins found naturally inside cells throughout the body, where it is thought to help manage actin, a structural protein cells rely on to change shape and move. That natural role in cell movement is what led researchers to study whether giving extra thymosin beta-4 could support the kind of cell migration and reorganization involved in healing.

Because it occurs naturally rather than being an entirely synthetic invention, researchers have been able to study both the full-length, 43-amino-acid protein and shorter fragments derived from it, including the actin-binding piece marketed separately as TB-500. The full-length protein has its own, largely separate, human trial record covering wound healing, heart tissue, and eye-surface healing.

How it is studied

Human research on thymosin beta-4 includes a first-in-human safety and pharmacokinetic study in healthy volunteers given the peptide intravenously, a small pilot study in patients recovering from a heart attack in which cells were treated with the peptide before being transplanted back into the patient, and a randomized, placebo-controlled trial of a topical eye-drop formulation in people with dry eye. That combination of a formal safety study alongside condition-specific pilot trials gives thymosin beta-4 a somewhat more structured human evidence base than many other short research peptides, though each individual trial remains small by the standards of an approved medicine's development program.

What studies report

• A first-in-human, placebo-controlled study across single and multiple intravenous amounts in healthy volunteers reported no limiting toxicity at any amount tested and an overall favorable safety profile. [3]
• A randomized, placebo-controlled trial of a topical eye-drop formulation in 72 participants did not find a significant difference from placebo on its two main measures, overall eye discomfort and one area of corneal surface staining, but did find significant improvement on several other measures, including discomfort during a standardized environmental challenge and staining in two other areas of the cornea. [2]
• A ten-patient pilot study in people recovering from a heart attack, in which half received transplanted cells pre-treated with thymosin beta-4 and half received untreated transplanted cells, reported a larger improvement in six-minute walking distance and heart function in the pre-treated group after six months, with no severe procedure-related complications in either group. [1]

What is not known

Outside of the eye-drop trial, the human evidence for thymosin beta-4 rests on small, early-phase studies rather than large, confirmatory trials, and no medicine built on the full-length protein has reached approval anywhere. The heart attack pilot tested the peptide as a cell pre-treatment in only ten patients, not as a stand-alone injected drug, so it does not show what an injection of the peptide alone would do after a heart attack. The dry eye trial missed its own primary measures, so its positive secondary results should be read as suggestive rather than confirmed. How thymosin beta-4's effects compare with the shorter TB-500 fragment studied separately remains an open question in the published record.

Regulatory status

Thymosin Beta-4 is not approved as a medicine anywhere. It has been studied in early-phase human trials for wound healing, heart tissue repair, and dry eye, but none of those research programs has resulted in a drug approval.